Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Febuxostat on Clinical Outcomes in Hemodialysis Patients with Secondary Hyperparathyroidism
TCTR20250427006Phase 0Not yet recruiting
- Sponsor
- Buriram Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 0, randomised trial of febuxostat in secondary hyperparathyroidism (SHPT) and end-stage kidney disease (ESKD), sponsored by Buriram Hospital. Planned start May 2025; status: not yet recruiting.
02
Drugs
febuxostat
03
Conditions
secondary hyperparathyroidism (SHPT)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on TCTR20250427006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250427006.